Compositions and Methods for Treating Disorders Associated with Abnormal Phosphate Metabolism

ABSTRACT

The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets. The present invention further provides methods and kits for diagnosing familial tumoral calcinosis as well as for identifying agents suitable for treating disorders associated with abnormal phosphate metabolism.

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to methods of treating disorders associated with abnormal phosphate metabolism, and more particularly to the use of regulators of GalNAc-T3 in the treatment of disorders associated with hyperphosphatemia such as Familial tumoral calcinosis (FTC), hyperphosphatemic calcinosis, hemodialysis, and chronic renal failure, as well as disorders associated with hypophosphatemia, e.g., X-linked vitamin D resistant hypophosphatemic rickets (HYP), hereditary hypercalciuria with hypophosphatemic rickets (HHRH), oncogenic hypophosphatemic osteomalacia (OHO), and X-linked hypophosphatemic rickets (PHEX).

Phosphate-related abnormalities (i.e., hypophosphatemia or hyperphosphatemia) characterize a class of metabolic disorders manifesting with hyper- and dys-lipidemia, rickets and/or serious metastatic calcification, which can eventually lead to death. These disorders result from disrupted phosphate metabolism. Inorganic phosphate is absorbed in the intestinal tract in a process regulated by 1α,25-dihydroxyvitamin D3 (vitamin D3). On the other hand, phosphate excretion, which is regulated by the parathyroid hormone, takes place in both kidney and intestinal tract (i.e., fecal excretion). Moreover, the liver, skin and kidney are involved in the conversion of vitamin D3 to its active metabolite, calcitriol, which plays an active role in maintaining phosphate balance and bone mineralization.

Under normal conditions, a decrease in plasma phosphate level stimulates the production of vitamin D3 in the renal proximal tubule, resulting in increased absorption of calcium and phosphate. The increase in calcium level leads to a secondary suppression of the parathyroid hormone (PTH), which results in upregulation of the sodium-dependent phosphate transport in the renal proximal tubule.

Hyperparathyroidism, a condition characterized by overproduction of PTH in the parathyroid glands, results in hypophosphatemia and increased phosphate excretion due to inhibition of sodium-dependent phosphate transport in the kidney.

Other conditions which involve hypophosphatemia include vitamin D deficiency, which causes rickets in children and osteomalacia in adults, X-linked vitamin D resistant hypophosphatemic rickets (HYP), hereditary hypercalciuria with hypophosphatemic rickets (HHRH), Dent's disease including certain types of renal Fanconi syndrome, renal I alpha-hydroxylase deficiency (VDDR 1), defects in 1,25-dihydroxy vitamin D3 receptor (end organ resistance, VDDR II), oncogenic hypophosphatemic osteomalacia (OHO), and X-linked hypophosphatemic rickets (PHEX) [Francis, Nat. Genet. (1995), 11: 130-136; Rowe, Hum. Genet. (1996), 97: 345-352; Rowe, Hum. Mol. Genet. (1997), 6: 539-549).

On the other hand, hyperphosphatemia, i.e., increased plasma level of PO₄, is often a result of renal insufficiency. End-stage renal insufficiency, a condition affecting approximately 250,000 individuals in the USA, can lead to metastatic calcification, i.e., the deposition of calcium phosphate in previously healthy connective tissues and solid organs. Thus, advanced renal failure, i.e., a glomerular filtration rate of less than 20 mL/min, causes a decrease in PO₄ excretion and an increase of plasma PO₄. However, other conditions may also decrease PO₄ excretion. These include pseudohypoparathyroidism or hypoparathyroidism. Hyperphosphatemia can also result from excess administration of oral PO₄, or from overuse of enema containing phosphate salts. Furthermore, hyperphosphatemia may result from migration of intracellular PO₄ to the cell exterior. Such migration frequently occurs in diabetic ketoacidosis (regardless of systemic PO₄ loss), bruise, non-traumatic rhabdomyolysis, systemic infection and tumor lysis syndrome. Moreover, hyperphosphatemia plays a critical role in the onset of secondary hyperparathyroidism, and the onset of renal osteodystrophy in patients under dialysis treatment for a long period.

Familial tumoral calcinosis (FTC; MIM211900) is a severe autosomal recessive metabolic disorder manifesting with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues, especially of the hips and knees. Hyperphosphatemia, secondary to increased renal phosphate retention, is the major metabolic abnormality associated with familial tumoral calcinosis (FTC) and is accompanied by inappropriately normal or elevated levels of PTH and 1,25-dihydroxyvitamin D3, two essential regulators of phosphate metabolism [Steinherz, 1985 (Supra)]. While hyperphosphatemia appears in FTC patients as early as 21 months of age, the calcium deposits are noted later in childhood. Thus, all FTC patients have elevated serum phosphorus levels, and in some patients, elevated levels of 1,25-vitamin D are also detected. FTC represents the metabolic mirror image of hypophosphatemic rickets caused by mutations in PHEX (MIM307800) and in FGF23 (MIM193100) genes [Schiavi, S. C. and Kumar, R. Kidney Int. 65, 1-14 (2004); Quarles, L. D. Am. J. Physiol. Endocrinol. Metab. 285, 1-9 (2003)] and which is characterized by decreased phosphate levels, decreased renal tubular phosphate reabsorption and inappropriately normal or decreased levels of 1,25-dihydroxyvitamin D3 [Prince M. J. et al. Ann Intern Med. 96, 586-591 (1982)].

Current treatment regimens of hypophosphatemia related disorders [e.g., hypophosphatemic rickets (PHEX)] include active vitamin D analogues (e.g., calcitriol) and oral phosphate supplementation. However, both of these nutrition supplements often fail to normalize serum phosphate level and in many cases, the patients fail to reach normal adult height. The recent use of recombinant human growth hormone (rhGH) was reported to benefit children with PHEX, however, is often associated with disproportional growth of the trunk (Reviewed in Reusz G, 2001, Orv Hetil. 142: 2659-65; Wilson D M 2000, J. Pediatr. Endocrinol. Metab. Suppl 2: 993-8).

Treatment of hyperphosphatemia involves the use of aluminum- or calcium-based phosphate-binding agents, which effectively lower serum phosphorus levels. However, while the use of aluminum-based agents can be associated with bone toxicity, renal osteodystrophy and encephalopathy, the use of calcium-based agents is often associated with hypercalaemia and cardiovascular calcification. To overcome these limitations, non-calcium-, non-aluminium-based alternative agents were developed. These include the sevelamer hydrochloride and lanthanum carbonate (Hutchison A J, 2004, Nephrol Dial Transplant. 19 Suppl 1:i19-24; Chertow G M., 2003, J Am Soc Nephrol. 14: S310-4). However, while lanthanum was found to be effective and well-tolerated (Joy M S et al., 2003, Am. J. Kidney Dis. 42: 96-107), sevelamer was found to be less effective than aluminum (Cizman B. 2003, Nephrol. Dial. Transplant. 18 Suppl 5:v47-9) and the use of both of these agents is limited by their high cost. Moreover, both of these agents treat only the symptoms by suppressing phosphate re-absorption in the intestinal track and not the causes which lead to hyperphosphatemia.

Thus, there is a need to develop pharmaceutical compositions and methods of treating disorders associated with phosphate metabolism devoid of the above limitations.

Phosphatonin is a novel circulating phosphaturic factor, postulated to be primarily responsible for modulating urinary phosphate excretion in a variety of hypophosphatemic disorders.

Quarles, 2003 (J Clin Invest. 112: 642-646), suggested that phosphatonin is a circulating protein that inhibits sodium-dependent phosphate reabsorption in the renal proximal tubule via mechanisms which are distinct from PTH, and vitamin D3. The fibroblast growth factor 23 (FGF23), secreted frizzled-related protein 4 (SFRP4) and matrix extracellular phosphoglycoprotein (MEPE) [Schiavi, S. C. and Kumar, R. Kidney Int. 65, 1-14 (2004); Quarles, L. D. Am. J. Physiol. Endocrinol. Metab. 285, 1-9 (2003)] were suggested as the putative phosphatonin proteins since they modulate circulating phosphate levels [Shimada, T. et al. Proc Natl Acad. Sci. 98, 6500-6505 (2001); Bowe A. E. et al. Bioch Biophys Res Comm. 284, 977-981 (2001); Rowe P. S. N. et al. Bone. 34, 303-319 (2003); Berndt, T. et al. J. Clin. Invest. 112, 785-794 (2003)].

Thus, FGF23 and other phosphatonin genes have been considered as prime candidates for the FTC gene [Jan De Beur, S. M., and Levine, M. A. (2002), J. Clin. Endocrinol. Metab. 87: 2467-2473].

While reducing the present invention to practice, the present inventors have uncovered that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause FTC. Thus, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets.

SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided a method of treating a disorder associated with abnormal phosphate metabolism comprising providing to an individual in need thereof an agent capable of regulating an expression level and/or activity of GalNAc-T3 thereby treating the disorder associated with abnormal phosphate metabolism in the individual.

According to another aspect of the present invention there is provided a use of an agent capable of regulating an expression level and/or activity of GalNAc-T3 for the treatment of a disorder associated with abnormal phosphate metabolism.

According to yet another aspect of the present invention there is provided a use of an agent capable of regulating an expression level and/or activity of GalNAc-T3 for the manufacture of a medicament identified for the treatment of a disorder associated with abnormal phosphate metabolism.

According to still another aspect of the present invention there is provided method of diagnosing familial tumoral calcinosis in an individual, the method comprising identifying in a polynucleotide sequence of the individual at least one nucleic acid substitution resulting in downregulation of an expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.

According to an additional aspect of the present invention there is provided a kit for diagnosing familial tumoral calcinosis in an individual, the kit comprising a packaging material packaging at least one reagent, the at least one reagent for identifying in a polynucleotide sequence of the individual at least one nucleic acid substitution resulting in downregulation of an expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.

According to yet an additional aspect of the present invention there is provided a method of diagnosing familial tumoral calcinosis in an individual, the method comprising identifying in a polypeptide sequence of the individual at least one amino acid substitution capable of downregulating expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.

According to yet another aspect of the present invention there is provided a method of identifying an agent suitable for treating a disorder associated with abnormal phosphate metabolism, comprising exposing GalNAc-T3 or cells expressing GalNAc-T3 to a plurality of molecules and selecting from the plurality of molecules at least one molecule capable of regulating the expression level and/or the activity of the GalNAc-T3, the at least one molecule being the agent suitable for treating the disorder associated with abnormal phosphate metabolism.

According to still an additional aspect of the present invention there is provided a kit for diagnosing familial tumoral calcinosis in an individual, the kit comprising a packaging material packaging at least one reagent, the at least one reagent for identifying in a polypeptide sequence of the individual at least one amino acid substitution capable of downregulating expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.

According to a further aspect of the present invention there is provided a method of identifying an agent suitable for treating a disorder associated with abnormal phosphate metabolism, comprising exposing GalNAc-T3 or cells expressing GalNAc-T3 to a plurality of molecules and selecting from the plurality of molecules at least one molecule capable of regulating the expression level and/or the activity of the GalNAc-T3, the at least one molecule being the agent suitable for treating the disorder associated with abnormal phosphate metabolism.

According to yet a further aspect of the present invention there is provided a kit for identifying an agent suitable for treating a disorder associated with abnormal phosphate metabolism, the kit comprising a packaging material packaging at least one reagent, the at least one reagent include GalNAc-T3 and/or cells expressing GalNAc-T3 and a plurality of molecules, wherein at least one molecule of the plurality of molecules is capable of regulating the expression level and/or activity of the GalNAC-T3, thereby identifying the agent suitable for treating a disorder associated with abnormal phosphate metabolism.

According to further features in preferred embodiments of the invention described below, the disorder is associated with hyperphosphatemia.

According to still further features in the described preferred embodiments the disorder associated with the hyperphosphatemia is selected from the group consisting of Familial tumoral calcinosis (FTC), hyperphosphatemic calcinosis, hemodialysis, and chronic renal failure.

According to still further features in the described preferred embodiments regulating is upregulating the expression level and/or activity of the GalNAc-T3.

According to still further features in the described preferred embodiments, upregulating the expression level and/or activity of the GalNAc-T3 is effected by an agent selected from the group consisting of:

(a) an exogenous polynucleotide encoding at least a functional portion of GALNT3;

(b) an agent capable of increasing expression of endogenous GalNAc-T3 in an individual;

(c) an agent capable of increasing endogenous GalNAc-T3 activity in an individual;

(d) an exogenous polypeptide including at least a functional portion of GalNAc-T3;

(e) a GalNAc-T3 substrate; and

(f) a GalNAc-T3-expressing cell.

According to still further features in the described preferred embodiments the exogenous polynucleotide encoding at least a functional portion of GALNT3 is set forth in SEQ ID NO:29.

According to still further features in the described preferred embodiments the GalNAc-T3 is set forth in SEQ ID NO:28.

According to still further features in the described preferred embodiments the disorder is associated with hypophosphatemia.

According to still further features in the described preferred embodiments the disorder associated with the hypophosphatemia is selected from the group consisting of X-linked vitamin D resistant hypophosphatemic rickets (HYP), hereditary hypercalciuria with hypophosphatemic rickets (HHRH), oncogenic hypophosphatemic osteomalacia (OHO), and X-linked hypophosphatemic rickets (PHEX).

According to still further features in the described preferred embodiments regulating is downregulating the expression level and/or the activity of the GalNAc-T3.

According to still further features in the described preferred embodiments downregulating the expression level and/or the activity of the GalNAc-T3 is effected by an agent selected from the group consisting of:

(a) a molecule which binds the GalNAc-T3;

(b) an enzyme which cleaves the GalNAc-T3;

(c) an antisense polynucleotide capable of specifically hybridizing with at least part of an mRNA transcript encoding GALNT3;

(d) a ribozyme which specifically cleaves at least part of an mRNA transcript encoding GALNT3;

(e) a small interfering RNA (siRNA) molecule which specifically cleaves at least part of a transcript encoding GALNT3;

(f) a non-functional analogue of at least a catalytic or binding portion of the GalNAc-T3;

(g) a molecule which prevents GalNAc-T3 activation or substrate binding.

According to still further features in the described preferred embodiments the mRNA transcript encoding GALNT3 is set forth in SEQ ID NO:29.

According to still further features in the described preferred embodiments the agent is formulated for systemic administration.

According to still further features in the described preferred embodiments the polynucleotide sequence is an mRNA sequence encoding GALNT3 or a genomic sequence region including the GALNT3 gene.

According to still further features in the described preferred embodiments the polynucleotide sequence is set forth by SEQ ID NO:29 or 33.

According to still further features in the described preferred embodiments identifying at least one nucleic acid substitution in the GALNT3 gene is effected using a method selected from the group consisting of DNA sequencing, restriction fragment length polymorphism (RFLP analysis), allele specific oligonucleotide (ASO) analysis, Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE), Single-Strand Conformation Polymorphism (SSCP) analysis, Dideoxy fingerprinting (ddF), pyrosequencing analysis, acycloprime analysis, Reverse dot blot, GeneChip microarrays, Dynamic allele-specific hybridization (DASH), Peptide nucleic acid (PNA) and locked nucleic acids (LNA) probes, TaqMan, Molecular Beacons, Intercalating dye, FRET primers, AlphaScreen, SNPstream, genetic bit analysis (GBA), Multiplex minisequencing, SNaPshot, MassEXTEND, MassArray, GOOD assay, Microarray miniseq, arrayed primer extension (APEX), Microarray primer extension, Tag arrays, Coded microspheres, Template-directed incorporation (TDI), fluorescence polarization, Colorimetric oligonucleotide ligation assay (OLA), Sequence-coded OLA, Microarray ligation, Ligase chain reaction, Padlock probes, Rolling circle amplification, and Invader assay.

According to still further features in the described preferred embodiments identifying the at least one nucleic acid substitution in the mRNA sequence encoding the GALNT3 is effected using DNA sequencing of a GLANT3 RT-PCR product.

According to still further features in the described preferred embodiments the polypeptide sequence is set forth in SEQ ID NO:28.

According to still further features in the described preferred embodiments identifying the at least one amino acid substitution is effected using an antibody capable of differentially binding to at least one polymorph of the GalNAc-T3, the at least one polymorph includes the amino acid substitution capable of down-regulating the expression level and/or the activity of GalNAc-T3.

According to still further features in the described preferred embodiments the GalNAc-T3 includes at least a catalytic or binding portion of the GalNAc-T3.

According to still further features in the described preferred embodiments the GalNAc-T3 is set forth in SEQ ID NO:28.

According to still further features in the described preferred embodiments the cells expressing GalNAc-T3 are selected from the group consisting of kidney cells, fibroblasts, epithelial cells, lymphocytes, bone marrow cells, lung cells, liver cells and brain cells.

According to still further features in the described preferred embodiments the expression level is detected using an immunological detection method and/or an RNA detection method.

According to still further features in the described preferred embodiments the immunological detection method is selected from the group consisting of a radio-immunoassay (RIA), an enzyme linked immunosorbent assay (ELISA), a western blot, an immunohistochemical analysis, and a fluorescence activated cell sorting (FACS).

According to still further features in the described preferred embodiments the RNA detection method is selected from the group consisting of Northern Blot, RT-PCR, RNA in situ hybridization, and in situ RT-PCR.

According to still further features in the described preferred embodiments the activity is determined using an activity assay selected from the group consisting of in situ activity assay and in vitro activity assays.

According to still further features in the described preferred embodiments the activity assay is effected using a substrate selected from the group consisting of HIVH1Bgp120, Fibronectin, Prion-a, CD59, Muc1a, Muc2, EA2, Muc7.

The present invention successfully addresses the shortcomings of the presently known configurations by providing methods of treating disorders associate with abnormal phosphate metabolism.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIGS. 1 a-b are diagrams illustrating mapping of the familial tumoral calcinosis (FTC) critical region. Shown are haplotype analyses of a consanguinity FTC family (Family 1, FIG. 1 a) and a non-consanguinity FTC family (Family 2, FIG. 1 b) using polymorphic microsatellite markers on chromosome 2q24-q31.1. The shared disease-associated haplotypes of all participating individuals are indicated by boxes. The noted DNA markers correspond to the following GenBank Accession numbers: G08198 (D2S1399), G07884 (D2S1353); Z16431 (D2S111), Z54008 (D2S2330), G08153 (D2S1379), Z24635 (D2S399), Z50933 (D2S2345), G08180 (D2S1776), Z53666 (D2S2299), Z16821 (D2S142), Z53511 (D2S2284), Z52323 (D2S2177), and G08168 (D2S1391).

FIGS. 2 a-b are photographs illustrating the clinical features of FTC. FIG. 2 a—a large subcutaneous tumor over the left outer thigh of patient No. 01001 of family 1. FIG. 2 b—a periarticular calcified mass over the left acetabulum of patient No. 01006 of family 1.

FIGS. 3 a-b are multipoint LOD score analyses of a consanguinity FTC family (Family 1, FIG. 3 a) and a non-consanguinity FTC family (Family 2, FIG. 3 b). FIG. 3 a—homozygosity mapping for 12 informative markers spanning 18.1 cM. Note the maximum multipoint LOD score of 6.7 at D2S111 (HOMOZ). FIG. 3 b—multipoint linkage map using 7 microsatellite markers. Note the peak LOD of 3.4 for markers D2S2363 and D2S1379 (GeneHunter).

FIG. 4 illustrates RT-PCR determination of GALNT3 gene expression. RNA samples were extracted from various human tissues and the RT-PCR reaction was performed using the GALex6F (SEQ ID NO:23 and GALex9R (SEQ ID NO:25) primers followed by nested PCR using the GALex6F and GALex8R (SEQ ID NO:24) primers which are specific for GALNT3 transcript. Note the high-intensity bands obtained in RNA samples obtained from the skin, bone marrow and kidney. The RT-PCR product of the β-actin transcript (obtained using the Actin 5′ and Actin 3′ primers, SEQ ID NOs:26 and 27) was used as a measure of the level of RNA in each sample.

FIGS. 5 a-d illustrate GALNT3 mutation analysis in FTC families. Shown are DNA sequencing chromatograms depicting the genomic sequence of exon 1 (FIGS. 5 a-b) and exon 7 (FIG. 5 c-d) of the GALNT3 gene in two FTC families. FIG. 5 a—the wildtype sequence of exon 1 in family 1; FIG. 5 b—the presence of a heterozygous C→T transition at position 484 of the GALNT3 mRNA sequence (GenBank Accession No. NM_(—)004482, SEQ ID NO:29) creating a TGA termination codon (R162X) in exon 1 of affected individuals of family 2; FIG. 5 c—the presence of a homozygous G→A transition at position 1524+1 (GALNT3 genomic contig GenBank Accession No. NT_(—)005403) in affected individuals of family 1, FIG. 5 d—the presence of a heterozygous G→A transition at position 1524+5 (GenBank Accession No. NT_(—)005403) in all affected individuals of family 2.

FIGS. 6 a-b are RFLP analyses depicting the segregation of the pathogenic mutations in families 1 and 2. FIG. 6 a—segregation of the 1524+1G→A mutation in family 1. The 1524+1G→A nucleic acid change abolishes a recognition site for BsaAI; consequently, digestion of a PCR amplicon encompassing exon 7 generates an homozygous (uncut) 423 bp product in affected individuals, while heterozygous carriers of the mutation display an additional fragment of 314 bp. FIG. 6 b—segregation of the 1524+5G→A and R162X mutations in family 2. The 1524+5G→A and R162X nucleic acid changes create novel recognition sites for endonucleases SspI (upper gel) and DdeI (lower gel) respectively; hence, affected individuals in family 2 display an additional fragment upon digestion of the relevant PCR amplicons (exons 7 and 1, respectively) with the corresponding restriction enzymes.

FIG. 7 is an RT-PCR analysis depicting the expression of GALNT3. RNA samples extracted from skin (lanes 1, 3, 5, 7) or blood lymphocytes (lanes 2, 4, 6, 8) of a healthy individual (lanes 1-4) and an FTC affected individual (patient No. 01001 of family 1, lanes 5-8) were subjected to RT-PCR analysis using the GALNT3 (lanes 1-2, 5-6) or β-actin (ACTB, lanes 3-4, 7-8) PCR primers as described in FIG. 4 hereinabove. Note the aberrant low-intensity, low-molecular weight GALNT3 RT-PCR products obtained using RNA from skin (lane 5, arrow) and blood lymphocytes (lane 6) of the FTC affected individual as compared with the high-intensity GALNT3 RT-PCR products obtained using RNA from skin (lane 1) and blood lymphocytes (lane 2) of the healthy individual. Also note the similar intensity bands of β-actin RT-PCR products in both affected and healthy individuals (compare lanes 3-4 to lanes 7-8).

FIG. 8 is a DNA sequencing chromatogram depicting the absence of exon 7 in a blood RNA sample of an FTC affected individual. Sequence analysis was performed on the aberrant low-molecular weight RT-PCR product observed in FIG. 7 lane 6 using the GALex6F (SEQ ID NO:23) and GALex8R (SEQ ID NO:24) nested PCR primers. Note the absence of exon 7 sequence in the aberrant low-molecular weight splice product from the blood sample of the affected individual.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of upregulators and downregulators of GalNAc-T3 which can be used in treating disorders associated with abnormal phosphate levels. Specifically, the present invention can be used to treat familial tumoral calcinosis and other disorders associated with hyperphosphatemia, as well as disorders associated with hypophosphatemia.

The principles and operation of the methods of treating disorders associated with abnormal phosphate metabolism according to the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

Familial tumoral calcinosis (FTC; MIM211900) is a severe autosomal recessive metabolic disorder manifesting with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Current methods of treating patients affected with this disease and other hyperphosphatemia-related disorders (e.g., end-stage renal failure, pseudohypoparathyroidism, hypoparathyroidism) include the use of aluminum- or calcium-based phosphate-binding agents. However, these phosphate-binders can cause bone toxicity, renal osteodystrophy, encephalopathy, hypercalcaemia and cardiovascular calcification. To overcome these limitations, aluminum and calcium free agents such as sevelamer hydrochloride and lanthanum carbonate were suggested for treatment of hyperphosphatemia (FOSRENOL®, AnorMED Inc.; Hutchison A J, 2004, Nephrol Dial Transplant. 19 Suppl 1:i19-24; Chertow G M., 2003, J Am Soc Nephrol. 14: S310-4). These agents suppress phosphate re-absorption in the intestinal track. Although safer than aluminum, sevelamer was found to be less effective than the aluminum-based phosphate binder (Cizman B. 2003, Nephrol. Dial. Transplant. 18 Suppl 5:v47-9). On the other hand, lanthanum was found to be effective and well-tolerated (Joy M S et al., 2003, Am. J. Kidney Dis. 42: 96-107). However, both of these expensive agents are used for treating the symptoms and not the cause of hyperphosphatemia.

While reducing the present invention to practice, the present inventors have uncovered deleterious mutations in the GALNT3 gene encoding GalNAc-T3 in individuals affected with familial tumoral calcinosis (FTC). Moreover, the present inventors have uncovered that inducers of GalNAc-T3 can be used in treating FTC and other hyperphosphatemia-related disorders, and that inhibitors of GalNAc-T3 can be used to treat hypophosphatemia-related disorders.

Thus, according to one aspect of the present invention there is provided a method of treating a disorder associated with abnormal phosphate metabolism in an individual.

As used herein, the term “individual” refers to a human being suffering from a disease associated with abnormal phosphate level, i.e., hyperphosphatemia or hypophosphatemia due to a genetic disease (e.g., an individual having familial tumoral calcinosis), hormonal imbalance (e.g., hyperparathyroidism), renal disease (as a result of e.g., hemodialysis) and the like.

The phrase “treating” refers to inhibiting or arresting the development of a disease, disorder or condition and/or causing the reduction, remission, or regression of a disease, disorder or condition in an individual suffering from, or diagnosed with, the disease, disorder or condition. Those of skill in the art will be aware of various methodologies and assays which can be used to assess the development of a disease, disorder or condition, and similarly, various methodologies and assays which can be used to assess the reduction, remission or regression of a disease, disorder or condition.

As used herein “abnormal phosphate metabolism” refers to abnormal levels of serum phosphate, which may reflect abnormal absorption of phosphate in the intestinal tract or abnormal phosphate excretion in both the kidney and intestinal tract (i.e., via fecal excretion). Thus, any deviation from the normal range of phosphate in the plasma (i.e., 2.5-4.5 mg/dl), can be referred to as being abnormal.

The phrase “disorder associated with abnormal phosphate metabolism” refers to hyper- or hypophosphatemia-related disorders, i.e., the presence of excess of phosphate in the serum (i.e., above 4.5 mg/dl) or insufficient levels of phosphate (i.e., under 2.5 mg/dl), respectively.

The method according to this aspect of the present invention is effected by providing to an individual in need thereof an agent capable of regulating an expression level and/or activity of GalNAc-T3.

The term “GalNAc-T3” as used herein refers to the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3, which a member of the GalNAc-transferases family. Protein members of this family (e.g., GalNAc-T2, -T4, -T6, -T8) transfer N-acetyl galactosamine to the hydroxyl group of a serine or threonine residue in the first step of O-linked oligosaccharide biosynthesis. Individual GalNAc-transferase proteins have distinct activities and initiation of O-glycosylation is regulated by a repertoire of GalNAc-transferases. It will be appreciated that although these proteins share high sequence homology, each of the GalNAc-transferase proteins exhibits different substrate specificities. For example, the GalNAc-T3 exhibits substrate specificity towards HIV_(HIB)gp120, Fibronectin, Prion-a, CD59, Muc1a, Muc2, EA2, and Muc7.

The term “regulating” as used herein refers to upregulating (i.e., increasing) or downregulating (i.e., inhibiting or decreasing) of the expression and/or activity of GalNAc-T3.

According to preferred embodiments of the present invention the disorder associated with abnormal phosphate metabolism is hyperphosphatemia and thus the method of the present invention is effected by upregulating expression or activity of GalNAc-T3. Non-limiting examples of hyperphosphatemia-related disorders which can be treated according to this aspect of the present invention include familial tumoral calcinosis (FTC), hyperphosphatemic calcinosis, hemodialysis, chronic renal failure and end-stage renal failure.

Upregulation of GalNAc-T3 can be effected at the genomic level (i.e., activation of transcription via promoters, enhancers, regulatory elements), at the transcript level (i.e., correct splicing, polyadenylation, activation of translation) or at the protein level (i.e., post-translational modifications, interaction with substrates and the like).

Following is a list of agents capable of upregulating the expression level and/or activity of GalNAc-T3.

An agent capable of upregulating expression level of a GalNAc-T3 may be an exogenous polynucleotide sequence designed and constructed to express at least a functional portion of the GalNAc-T3 protein. Accordingly, the exogenous polynucleotide sequence may be a DNA or RNA sequence encoding a GalNAc-T3 molecule, capable of modulating phosphate metabolism.

The phrase “functional portion” as used herein refers to part of the GalNAc-T3 protein (i.e., a polypeptide) which exhibits functional properties of the enzyme such as binding to a substrate. According to preferred embodiments of the present invention the functional portion of GalNAc-T3 is a polypeptide sequence including amino acids 188-374 (region of glycosyl transferase) and/or 507-629 (region of ricin-type beta trefoil) as set forth in SEQ ID NO:28. Preferably, the functional portion of GalNAc-T3 is a polypeptide sequence including amino acids 13-633, more preferably, amino acids 1-633 as set forth in SEQ ID NO:28.

GalNAc-T3 has been cloned from human and mouse sources. Thus, coding sequences information for GalNAc-T3 is available from several databases including the GenBank database available through http://www.ncbi.nlm.nih.gov/.

To express exogenous GalNAc-T3 in mammalian cells, a polynucleotide sequence encoding a GalNAc-T3 (GenBank Accession number NM_(—)004482, SEQ ID NO:29) is preferably ligated into a nucleic acid construct suitable for mammalian cell expression. Such a nucleic acid construct includes a promoter sequence for directing transcription of the polynucleotide sequence in the cell in a constitutive or inducible manner.

It will be appreciated that the nucleic acid construct of the present invention can also utilize GalNAc-T3 homologues which exhibit the desired activity (i.e., transferring N-acetyl galactosamine to the hydroxyl group of a serine or threonine residue in the first step of O-linked oligosaccharide biosynthesis). Such homologues can be, for example, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO:29, as determined using the BestFit software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap weight equals 50, length weight equals 3, average match equals 10 and average mismatch equals −9.

Constitutive promoters suitable for use with the present invention are promoter sequences which are active under most environmental conditions and most types of cells such as the cytomegalovirus (CMV) and Rous sarcoma virus (RSV). Inducible promoters suitable for use with the present invention include for example the inducible promoter of the alkaline phosphates gene (Dollard M A and Billard P J. 2003. Whole-cell bacterial sensors for the monitoring of phosphate bioavailability. Microbiol. Methods, 55: 221-9) and the tetracycline-inducible promoter (Zabala M, et al., Cancer Res. 2004, 64(8): 2799-804).

The nucleic acid construct (also referred to herein as an “expression vector”) of the present invention includes additional sequences which render this vector suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., shuttle vectors). In addition, a typical cloning vectors may also contain a transcription and translation initiation sequence, transcription and translation terminator and a polyadenylation signal.

Eukaryotic promoters typically contain two types of recognition sequences, the TATA box and upstream promoter elements. The TATA box, located 25-30 base pairs upstream of the transcription initiation site, is thought to be involved in directing RNA polymerase to begin RNA synthesis. The other upstream promoter elements determine the rate at which transcription is initiated.

Enhancer elements can stimulate transcription up to 1,000 fold from linked homologous or heterologous promoters. Enhancers are active when placed downstream or upstream from the transcription initiation site. Many enhancer elements derived from viruses have a broad host range and are active in a variety of tissues. For example, the SV40 early gene enhancer is suitable for many cell types. Other enhancer/promoter combinations that are suitable for the present invention include those derived from polyoma virus, human or murine cytomegalovirus (CMV), the long term repeat from various retroviruses such as murine leukemia virus, murine or Rous sarcoma virus and HIV. See, Enhancers and Eukaryotic Expression, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 1983, which is incorporated herein by reference.

In the construction of the expression vector, the promoter is preferably positioned approximately the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

Polyadenylation sequences can also be added to the expression vector in order to increase the efficiency of GalNAC-T3 mRNA translation. Two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are suitable for the present invention include those derived from SV40.

In addition to the elements already described, the expression vector of the present invention may typically contain other specialized elements intended to increase the level of expression of cloned nucleic acids or to facilitate the identification of cells that carry the recombinant DNA. For example, a number of animal viruses contain DNA sequences that promote the extra chromosomal replication of the viral genome in permissive cell types. Plasmids bearing these viral replicons are replicated episomally as long as the appropriate factors are provided by genes either carried on the plasmid or with the genome of the host cell.

The vector may or may not include a eukaryotic replicon. If a eukaryotic replicon is present, then the vector is amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is possible. Instead, the recombinant DNA integrates into the genome of the engineered cell, where the promoter directs expression of the desired nucleic acid.

The expression vector of the present invention can further include additional polynucleotide sequences that allow, for example, the translation of several proteins from a single mRNA such as an internal ribosome entry site (IRES) and sequences for genomic integration of the promoter-chimeric polypeptide.

Examples for mammalian expression vectors include, but are not limited to, pcDNA3, pcDNA3.1 (+/−), pGL3, pZeoSV2(+/−), pSecTag2, pDisplay, pEF/myc/cyto, pCMV/myc/cyto, pCR3.1, pSinRep5, DH26S, DHBB, pNMT1, pNMT41, pNMT81, which are available from Invitrogen, pCI which is available from Promega, pMbac, pPbac, pBK-RSV and pBK-CMV which are available from Strategene, pTRES which is available from Clontech, and their derivatives.

Expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses can be also used. SV40 vectors include pSVT7 and pMT2. Vectors derived from bovine papilloma virus include pBV-1MTHA, and vectors derived from Epstein Bar virus include pHEBO, and p2O5. Other exemplary vectors include pMSG, pAV009/A⁺, pMTO10/A⁺, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV-40 early promoter, SV-40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

As described above, viruses are very specialized infectious agents that have evolved, in many cases, to elude host defense mechanisms. Typically, viruses infect and propagate in specific cell types. The targeting specificity of viral vectors utilizes its natural specificity to specifically target predetermined cell types and thereby introduce a recombinant gene into the infected cell. Thus, the type of vector used by the present invention will depend on the cell type transformed. The ability to select suitable vectors according to the cell type transformed is well within the capabilities of the ordinary skilled artisan and as such no general description of selection consideration is provided herein. For example, bone marrow cells can be targeted using the human T cell leukemia virus type I (HTLV-I) and kidney cells may be targeted using the heterologous promoter present in the baculovirus Autographa californica nucleopolyhedrovirus (AcMNPV) as described in Liang C Y et al., 2004 (Arch Virol. 149: 51-60).

Recombinant viral vectors are useful for in vivo expression of GalNAC-T3 since they offer advantages such as lateral infection and targeting specificity. Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.

Various methods can be used to introduce the expression vector of the present invention into stem cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et at. [Biotechniques 4 (6): 504-512, 1986] and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see U.S. Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods.

Introduction of nucleic acids by viral infection offers several advantages over other methods such as lipofection and electroporation, since higher transfection efficiency can be obtained due to the infectious nature of viruses.

It will be appreciated that upregulation of GalNAc-T3 can be also effected by administration of GalNAc-T3-expressing cells into the individual.

GalNAc-T3-expressing cells can be any suitable cells, such as kidney, bone marrow, keratinocyte and lymphocyte cells which are derived from the individuals and are transfected ex vivo with an expression vector containing the polynucleotide designed to express GalNAc-T3 as described hereinabove.

Administration of the GalNAc-T3-expressing cells of the present invention can be effected using any suitable route such as intravenous, intra peritoneal, intra kidney, intra gastrointestinal track, subcutaneous, transcutaneous, intramuscular, intracutaneous, intrathecal, epidural and rectal. According to presently preferred embodiments, the GalNAc-T3-expressing cells of the present invention are introduced to the individual using intravenous, intra kidney, intra gastrointestinal track and/or intra peritoneal administrations.

GalNAc-T3-expressing cells of the present invention can be derived from either autologous sources such as self bone marrow cells or from allogeneic sources such as bone marrow or other cells derived from non-autologous sources. Since non-autologous cells are likely to induce an immune reaction when administered to the body several approaches have been developed to reduce the likelihood of rejection of non-autologous cells. These include either suppressing the recipient immune system or encapsulating the non-autologous cells or tissues in immunoisolating, semipermeable membranes before transplantation.

Encapsulation techniques are generally classified as microencapsulation, involving small spherical vehicles and macroencapsulation, involving larger flat-sheet and hollow-fiber membranes (Uludag, H. et al. Technology of mammalian cell encapsulation. Adv Drug Deliv Rev. 2000; 42: 29-64).

Methods of preparing microcapsules are known in the arts and include for example those disclosed by Lu M Z, et al., Cell encapsulation with alginate and alpha-phenoxycinnamylidene-acetylated poly(allylamine). Biotechnol Bioeng. 2000, 70: 479-83, Chang T M and Prakash S. Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms. Mol Biotechnol. 2001, 17: 249-60, and Lu M Z, et al., A novel cell encapsulation method using photosensitive poly(allylamine alpha-cyanocinnamylideneacetate). J Microencapsul. 2000, 17: 245-51.

For example, microcapsules are prepared by complexing modified collagen with a ter-polymer shell of 2-hydroxyethyl methylacrylate (HEMA), methacrylic acid (MAA) and methyl methacrylate (MMA), resulting in a capsule thickness of 2-5 μm. Such microcapsules can be further encapsulated with additional 2-5 μm ter-polymer shells in order to impart a negatively charged smooth surface and to minimize plasma protein absorption (Chia, S. M. et al. Multi-layered microcapsules for cell encapsulation Biomaterials. 2002 23: 849-56).

Other microcapsules are based on alginate, a marine polysaccharide (Sambanis, A. Encapsulated islets in diabetes treatment. Diabetes Thechnol. Ther. 2003, 5: 665-8) or its derivatives. For example, microcapsules can be prepared by the polyelectrolyte complexation between the polyanions sodium alginate and sodium cellulose sulphate with the polycation poly(methylene-co-guanidine) hydrochloride in the presence of calcium chloride.

It will be appreciated that cell encapsulation is improved when smaller capsules are used. Thus, the quality control, mechanical stability, diffusion properties, and in vitro activities of encapsulated cells improved when the capsule size was reduced from 1 mm to 400 μm (Canaple L. et al., Improving cell encapsulation through size control. J Biomater Sci Polym Ed. 2002; 13: 783-96). Moreover, nanoporous biocapsules with well-controlled pore size as small as 7 nm, tailored surface chemistries and precise microarchitectures were found to successfully immunoisolate microenvironments for cells (Williams D. Small is beautiful: microparticle and nanoparticle technology in medical devices. Med Device Technol. 1999, 10: 6-9; Desai, T. A. Microfabrication technology for pancreatic cell encapsulation. Expert Opin Biol Ther. 2002, 2: 633-46).

An agent capable of upregulating a GalNAc-T3 may also be any compound which is capable of increasing the transcription and/or translation of an endogenous DNA or mRNA encoding the GalNAc-T3 and thus increasing endogenous GalNAc-T3 activity.

An agent capable of upregulating a GalNAc-T3 may also be an exogenous polypeptide including at least a functional portion (as described hereinabove) of the GalNAc-T3.

Upregulation of GalNAc-T3 can be also achieved by introducing at least one GalNAc-T3 substrate. Non-limiting examples of such agents include HIV_(HIB)gp120, Fibronectin, Prion-a, CD59, Muc1a, Muc2, EA2, Muc7.

It will be appreciated that since GalNAc-T3 participates in phosphate metabolism downregulation thereof can be utilized to treat disorders which involve in hypophosphatemia, i.e., reduced levels of plasma phosphate.

Thus, according to another preferred embodiments of the present invention the disorder associated with abnormal phosphate metabolism is hypophosphatemia and the method of the present invention is effected by downregulating GalNAc-T3 expression or activity. Non-limiting examples of hypophosphatemia-related disorders which can be treated according to the method of the present invention include X-linked vitamin D resistant hypophosphatemic rickets (HYP), hereditary hypercalciuria with hypophosphatemic rickets (HHRH), oncogenic hypophosphatemic osteomalacia (OHO), X-linked hypophosphatemic rickets (PHEX) and hyperparathyroidism.

Downregulation of GalNAc-T3 can be effected on the genomic and/or the transcript level using a variety of molecules which interfere with transcription and/or translation (e.g., antisense, siRNA, Ribozyme, DNAzyme), or on the protein level using e.g., antagonists, enzymes that cleave the polypeptide and the like.

Following is a list of agents capable of downregulating expression level and/or activity of GalNAc-T3.

One example, of an agent capable of downregulating a GalNAc-T3 is an antibody or antibody fragment capable of specifically binding GalNAc-T3. Preferably, the antibody specifically binds at least one epitope of a GalNAc-T3. As used herein, the term “epitope” refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.

Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

The term “antibody” as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab′)2, and Fv that are capable of binding to macrophages. These functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab′, the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab′ fragments are obtained per antibody molecule; (3) (Fab′)2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab′)2 is a dimer of two Fab′ fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody (“SCA”), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab′ monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab′ fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides (“minimal recognition units”) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].

Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′).sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

Another agent capable of downregulating a GalNAc-T3 is a small interfering RNA (siRNA) molecule. RNA interference is a two step process. The first step, which is termed as the initiation step, input dsRNA is digested into 21-23 nucleotide (nt) small interfering RNAs (siRNA), probably by the action of Dicer, a member of the RNase III family of dsRNA-specific ribonucleases, which processes (cleaves) dsRNA (introduced directly or via a transgene or a virus) in an ATP-dependent manner. Successive cleavage events degrade the RNA to 19-21 bp duplexes (siRNA), each with 2-nucleotide 3′ overhangs [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002); and Bernstein Nature 409:363-366 (2001)].

In the effector step, the siRNA duplexes bind to a nuclease complex to from the RNA-induced silencing complex (RISC). An ATP-dependent unwinding of the siRNA duplex is required for activation of the RISC. The active RISC then targets the homologous transcript by base pairing interactions and cleaves the mRNA into 12 nucleotide fragments from the 3′ terminus of the siRNA [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002); Hammond et al. (2001) Nat. Rev. Gen. 2:110-119 (2001); and Sharp Genes. Dev. 15:485-90 (2001)]. Although the mechanism of cleavage is still to be elucidated, research indicates that each RISC contains a single siRNA and an RNase [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002)].

Because of the remarkable potency of RNAi, an amplification step within the RNAi pathway has been suggested. Amplification could occur by copying of the input dsRNAs which would generate more siRNAs, or by replication of the siRNAs formed. Alternatively or additionally, amplification could be effected by multiple turnover events of the RISC [Hammond et al. Nat. Rev. Gen. 2:110-119 (2001), Sharp Genes. Dev. 15:485-90 (2001); Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002)]. For more information on RNAi see the following reviews Tuschl ChemBiochem. 2:239-245 (2001); Cullen Nat. Immunol. 3:597-599 (2002); and Brantl Biochem. Biophys. Act. 1575:15-25 (2002).

Synthesis of RNAi molecules suitable for use with the present invention can be effected as follows. First, the GalNAc-T3 mRNA sequence is scanned downstream of the AUG start codon for AA dinucleotide sequences. Occurrence of each AA and the 3′ adjacent 19 nucleotides is recorded as potential siRNA target sites. Preferably, siRNA target sites are selected from the open reading frame, as untranslated regions (UTRs) are richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex [Tuschl, T. 2001, ChemBiochem. 2:239-245]. It will be appreciated though, that siRNAs directed at untranslated regions may also be effective, as demonstrated for GAPDH wherein siRNA directed at the 5′ UTR mediated about 90% decrease in cellular GAPDH mRNA and completely abolished protein level (www.ambion.com/techlib/tn/91/912.html).

Second, potential target sites are compared to an appropriate genomic database (e.g., human, mouse, rat etc.) using any sequence alignment software, such as the BLAST software available from the NCBI server (www.ncbi.nlm.nih.gov/BLAST/). Putative target sites which exhibit significant homology to other coding sequences are filtered out.

Qualifying target sequences are selected as template for siRNA synthesis. Preferred sequences are those including low G/C content as these have proven to be more effective in mediating gene silencing as compared to those with G/C content higher than 55%. Several target sites are preferably selected along the length of the target gene for evaluation. For better evaluation of the selected siRNAs, a negative control is preferably used in conjunction. Negative control siRNA preferably include the same nucleotide composition as the siRNAs but lack significant homology to the genome. Thus, a scrambled nucleotide sequence of the siRNA is preferably used, provided it does not display any significant homology to any other gene.

For example, a suitable GalNAc-T3 siRNA can be the siRNA ID 14834 (Ambion Inc., Austin, Tex.).

Another agent capable of downregulating a GalNAc-T3 is a DNAzyme molecule capable of specifically cleaving an mRNA transcript or DNA sequence of the GalNAc-T3. DNAzymes are single-stranded polynucleotides which are capable of cleaving both single and double stranded target sequences (Breaker, R. R. and Joyce, G. Chemistry and Biology 1995; 2:655; Santoro, S. W. & Joyce, G. F. Proc. Natl, Acad. Sci. USA 1997; 943:4262). A general model (the “10-23” model) for the DNAzyme has been proposed. “10-23” DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (Santoro, S. W. & Joyce, G. F. Proc. Natl, Acad. Sci. USA 199; for rev of DNAzymes see Khachigian, L M [Curr Opin Mol Ther 4:119-21 (2002)].

Examples of construction and amplification of synthetic, engineered DNAzymes recognizing single and double-stranded target cleavage sites have been disclosed in U.S. Pat. No. 6,326,174 to Joyce et al. DNAzymes of similar design directed against the human Urokinase receptor were recently observed to inhibit Urokinase receptor expression, and successfully inhibit colon cancer cell metastasis in vivo (Itoh et al, 20002, Abstract 409, Ann Meeting Am Soc Gen Ther. www.asgt.org). In another application, DNAzymes complementary to bcr-abl oncogenes were successful in inhibiting the oncogenes expression in leukemia cells, and lessening relapse rates in autologous bone marrow transplant in cases of CML and ALL.

Downregulation of a GalNAc-T3 can also be effected by using an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding the GalNAc-T3.

Design of antisense molecules which can be used to efficiently down-regulate a GalNAc-T3 must be effected while considering two aspects important to the antisense approach. The first aspect is delivery of the oligonucleotide into the cytoplasm of the appropriate cells, while the second aspect is design of an oligonucleotide which specifically binds the designated mRNA within cells in a way which inhibits translation thereof.

The prior art teaches of a number of delivery strategies which can be used to efficiently deliver oligonucleotides into a wide variety of cell types [see, for example, Luft J Mol Med 76: 75-6 (1998); Kronenwett et al. Blood 91: 852-62 (1998); Rajur et al. Bioconjug Chem 8: 935-40 (1997); Lavigne et al. Biochem Biophys Res Commun 237: 566-71 (1997) and Aoki et al. (1997) Biochem Biophys Res Commun 231: 540-5 (1997)].

In addition, algorithms for identifying those sequences with the highest predicted binding affinity for their target mRNA based on a thermodynamic cycle that accounts for the energetics of structural alterations in both the target mRNA and the oligonucleotide are also available [see, for example, Walton et al. Biotechnol Bioeng 65: 1-9 (1999)].

Such algorithms have been successfully used to implement an antisense approach in cells. For example, the algorithm developed by Walton et al. enabled scientists to successfully design antisense oligonucleotides for rabbit beta-globin (RBG) and mouse tumor necrosis factor-alpha (TNF alpha) transcripts. The same research group has more recently reported that the antisense activity of rationally selected oligonucleotides against three model target mRNAs (human lactate dehydrogenase A and B and rat gp130) in cell culture as evaluated by a kinetic PCR technique proved effective in almost all cases, including tests against three different targets in two cell types with phosphodiester and phosphorothioate oligonucleotide chemistries.

In addition, several approaches for designing and predicting efficiency of specific oligonucleotides using an in vitro system were also published (Matveeva et al., Nature Biotechnology 16: 1374-1375 (1998)].

For example, a suitable antisense oligonucleotides targeted against the GALNT3 mRNA (which is coding for the GalNAc-T3 protein) would be of the following sequences: CTGGCACATACACCTCTGG (SEQ ID NO:30).

Several clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides. For example, antisense oligonucleotides suitable for the treatment of cancer have been successfully used [Holmund et al., Curr Opin Mol Ther 1:372-85 (1999)], while treatment of hematological malignancies via antisense oligonucleotides targeting c-myb gene, p53 and Bcl-2 had entered clinical trials and had been shown to be tolerated by patients [Gerwitz Curr Opin Mol Ther 1:297-306 (1999)].

More recently, antisense-mediated suppression of human heparanase gene expression has been reported to inhibit pleural dissemination of human cancer cells in a mouse model [Uno et al., Cancer Res 61:7855-60 (2001)].

Thus, the current consensus is that recent developments in the field of antisense technology which, as described above, have led to the generation of highly accurate antisense design algorithms and a wide variety of oligonucleotide delivery systems, enable an ordinarily skilled artisan to design and implement antisense approaches suitable for downregulating expression of known sequences without having to resort to undue trial and error experimentation.

Another agent capable of downregulating a GalNAc-T3 is a ribozyme molecule capable of specifically cleaving an mRNA transcript encoding a GalNAc-T3. Ribozymes are being increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., Curr Opin Biotechnol. 9:486-96 (1998)]. The possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic research and therapeutic applications. In the therapeutics area, ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch et al., Clin Diagn Virol. 10:163-71 (1998)]. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation. Several ribozymes are in various stages of clinical trials. ANGIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials. ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis pathway. Ribozyme Pharmaceuticals, Inc., as well as other firms have demonstrated the importance of anti-angiogenesis therapeutics in animal models. HEPTAZYME, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals, Incorporated—WEB home page).

Another agent capable of downregulating GalNAc-T3 would be any molecule which binds to and/or cleaves GalNAc-T3. Such molecules can be GalNAc-T3 antagonists, or GalNAc-T3 inhibitory peptide.

It will be appreciated that a non-functional analogue of at least a catalytic or binding portion of GalNAc-T3 can be also used as an agent which down-regulates GalNAc-T3.

Another agent which can be used along with the present invention to downregulate GalNAc-T3 is a molecule which prevents GalNAc-T3 activation or substrate binding.

Each of the upregulating or downregulating agents described hereinabove or the expression vector encoding GalNAc-T3 can be administered to the individual per se or as part of a pharmaceutical composition which also includes a physiologically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.

As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

Herein the term “active ingredient” refers to the upregulating or downregulating agent or the expression vector encoding GalNAc-T3 which are accountable for the biological effect.

Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.

Herein the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

Techniques for formulation and administration of drugs may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition, which is incorporated herein by reference.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, inrtaperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (the upregulating or downregulating agent or the expression vector encoding GalNAc-T3) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., hyperphosphatemia or hypophosphatemia) or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1).

Dosage amount and interval may be adjusted individually to provide plasma levels of the active ingredient are sufficient to prevent hyperphosphatemia or hypophosphatemia (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as if further detailed above.

Thus, the teachings of the present invention can be used to treat individuals suffering from familial tumoral calcinosis (i.e., an hyperphosphatemia disorder). For example, an expression vector (e.g., a viral vector) including a polynucleotide sequence encoding the GALNT3 mRNA (SEQ ID NO:29) and the suitable promoter sequences to enable expression in kidney and skin cells is introduced into the individual via intravenous administration. Expression of such a vector in kidney and/or skin is expected to upregulate the expression level and/or activity of GalNAc-T3 in those tissues and thus to correct the hyperphosphatemia. Dosage of such an expression vector should be calibrated using cell culture experiments and animal models. Success of treatment is preferably evaluated by determining plasma phosphate levels and the individual general health status.

It will be appreciated, that if such a treatment is employed early in childhood, i.e., prior to the appearance of calcium deposits, or even prior to the detection of hyperphosphatemia (generally at 21 months of age), it may prevent the complications associated with such a disease (i.e., massive calcium deposits in the skin and subcutaneous tissues). In addition, since the expression vector is targeted to somatic cells which exhibit limited half-life (depending upon the cell line transduced), such a treatment is expected to be repeated periodically in order to prevent hyperphosphatemia.

As is shown in FIG. 5 c and Example 2 of the Examples section which follows, the present inventors have uncovered that a 1524+1G→A mutation in the GALNT3 gene, in a homozygous form, causes FTC in a consanguinity family (family 1). In addition, as is shown in FIGS. 5 b and d and Example 2 of the Examples section which follows, FTC affected members of the non-consanguinity family (family 2) are double heterozygous for the R162X and 1524+5G→A mutations in the GALNT3 gene. Thus, the presence of deleterious mutations in the GALNT3 sequence encoding GalNAc-T3 can be used in diagnosing FTC in an individual.

Thus, according to another aspect of the present invention there is provided a method of diagnosing familial tumoral calcinosis in an individual.

The method is effected by identifying in a polynucleotide sequence of the individual at least one nucleic acid substitution resulting in downregulation of an expression level and/or activity of GalNAc-T3.

As used herein the “polynucleotide sequence” refers to any DNA or RNA sequence which is derived from cells of the individual. DNA and RNA samples can be obtained from any source of cells. Preferably, the DNA is derived from peripheral blood cells (obtained using a syringe), skin cells (obtained from a skin biopsy) or mouth epithelial cells (obtained from a mouth wash), and the RNA is derived from blood or skin cells. Methods of extracting such DNA and RNA samples are well known in the art.

As is mentioned before, deleterious mutations in the GALNT3 gene cause FTC. Thus, according to preferred embodiments of the present invention the polynucleotide sequence is an mRNA sequence encoding GALNT3 (e.g., GenBank Accession No. NM_(—)004482, SEQ ID NO:29) or a genomic sequence region including the GALNT3 gene (e.g., SEQ ID NO:33).

As used herein, the phrase “nucleic acid substitution” refers to any mutation in the DNA sequence of an individual which can result in downregulation of the expression level and/or activity of GalNAc-T3. Non-limiting examples of such nucleic acid changes include a missense mutation (i.e., a mutation which changes an amino acid residue in the protein with another amino acid residue), a nonsense mutation (i.e., a mutation which introduces a stop codon in a protein), a frameshift mutation (i.e., a mutation, usually, deletion or insertion of nucleic acids which changes the reading frame of the protein, and may result in an early termination or in a longer amino acid sequence), a readthrough mutation (i.e., a mutation which results in an elongated protein due to a change in a coding frame or a modified stop codon), a promoter mutation (i.e., a mutation in a promoter sequence, usually 5′ to the transcription start site of a gene, which result in up-regulation or down-regulation of a specific gene product), a regulatory mutation (i.e., a mutation in a region upstream or downstream, or within a gene, which affects the expression of the gene product), a deletion (i.e., a mutation which deletes coding or non-coding nucleic acids in a gene sequence), an insertion (i.e., a mutation which inserts coding or non-coding nucleic acids into a gene sequence), an inversion (i.e., a mutation which results in an inverted coding or non-coding sequence), a splice mutation (i.e., a mutation which results in abnormal splicing or poor splicing) and a duplication (i.e., a mutation which results in a duplicated coding or non-coding sequence).

It will be appreciated that certain nucleic acid substitutions can be present in non-affected individuals [e.g., single nucleotide polymorphism (SNP)]. Such an SNP can cause, for example, a missense mutation in the GalNAc-T3, which, when present in the heterozygous form can be harmless, however, when present together with another, deleterious mutation such as a nonsense mutation, can lead to FTC at various degrees. Thus, according to preferred embodiments of the present invention the nucleic acid substitution is an SNP.

The nucleic acid substitution of the present invention can be identified using a variety of approaches suitable for identifying sequence alterations. One option is to determine the entire gene sequence of a PCR reaction product. Alternatively, a given segment of nucleic acid may be characterized on several other levels. At the lowest resolution, the size of the molecule can be determined by electrophoresis by comparison to a known standard run on the same gel. A more detailed picture of the molecule may be achieved by cleavage with combinations of restriction enzymes prior to electrophoresis, to allow construction of an ordered map. The presence of specific sequences within the fragment can be detected by hybridization of a labeled probe, or the precise nucleotide sequence can be determined by partial chemical degradation or by primer extension in the presence of chain-terminating nucleotide analogs.

Following is a non-limiting list of methods which can be used to identify the nucleic acid substitution and/or SNPs in the GALNT3 gene.

Direct sequencing of a PCR product: This method is based on the amplification of a genomic sequence using specific PCR primers in a PCR reaction following by a sequencing reaction utilizing the sequence of one of the PCR primers as a sequencing primer. Sequencing reaction can be performed using, for example, the Applied Biosystems (Foster City, Calif.) ABI PRISM® BigDye™ Primer or BigDye™ Terminator Cycle Sequencing Kits.

Restriction fragment length polymorphism (RFLP): This method uses a change in a single nucleotide (the SNP nucleotide) which modifies a recognition site for a restriction enzyme resulting in the creation or destruction of an RFLP.

For example, RFLP can be used to detect the R162X mutation (C→T substitution at nucleotide 484 as set forth in SEQ ID NO:29) in a genomic DNA of an individual. Briefly, genomic DNA is amplified using the GALe1bR (SEQ ID NO:1) and GALe1bF (SEQ ID NO:2) PCR primers, and the resultant PCR product is subjected to digestion using a restriction enzyme such as BstDEI, DdeI (see e.g., FIG. 6 b) or TspRI which are capable of differentially digesting a PCR product containing the T allele (and not the C allele) at position 484 of SEQ ID NO:29.

Single nucleotide mismatches in DNA heteroduplexes are also recognized and cleaved by some chemicals, providing an alternative strategy to detect single base substitutions, generically named the “Mismatch Chemical Cleavage” (MCC) (Gogos et al., Nucl. Acids Res., 18:6807-6817, 1990). However, this method requires the use of osmium tetroxide and piperidine, two highly noxious chemicals which are not suited for use in a clinical laboratory.

Allele specific oligonucleotide (ASO): In this method, an allele-specific oligonucleotide (ASO) is designed to hybridize in proximity to the polymorphic nucleotide, such that a primer extension or ligation event can be used as the indicator of a match or a mis-match. Hybridization with radioactively labeled allelic specific oligonucleotides (ASO) also has been applied to the detection of specific SNPs (Conner et al., Proc. Natl. Acad. Sci., 80:278-282, 1983). The method is based on the differences in the melting temperature of short DNA fragments differing by a single nucleotide. Stringent hybridization and washing conditions can differentiate between mutant and wild-type alleles.

It will be appreciated that ASO can be applied on a PCR product generated from genomic DNA. For example, to detect the R162X mutation, genomic DNA is amplified using the GALe1bR (SEQ ID NO:1) and the GALe1bF (SEQ ID NO:2) PCR primers, and the resultant PCR product is subjected to an ASO hybridization using the following oligonucleotide probe: 5′-CTTTGCACtGAGATCTTGG (SEQ ID NO:31) which is capable of hybridizing to the thymidine nucleotide at position 484 of SEQ ID NO:29. As a control for the hybridization, the CTTTGCACCGAGATCTTGG (SEQ ID NO:32) oligonucleotide probe is applied to detect the presence of the wildtype allele.

Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE): Two other methods rely on detecting changes in electrophoretic mobility in response to minor sequence changes. One of these methods, termed “Denaturing Gradient Gel Electrophoresis” (DGGE) is based on the observation that slightly different sequences will display different patterns of local melting when electrophoretically resolved on a gradient gel. In this manner, variants can be distinguished, as differences in melting properties of homoduplexes versus heteroduplexes differing in a single nucleotide can detect the presence of SNPs in the target sequences because of the corresponding changes in their electrophoretic mobilities. The fragments to be analyzed, usually PCR products, are “clamped” at one end by a long stretch of G-C base pairs (30-80) to allow complete denaturation of the sequence of interest without complete dissociation of the strands. The attachment of a GC “clamp” to the DNA fragments increases the fraction of mutations that can be recognized by DGGE (Abrams et al., Genomics 7:463-475, 1990). Attaching a GC clamp to one primer is critical to ensure that the amplified sequence has a low dissociation temperature (Sheffield et al., Proc. Natl. Acad. Sci., 86:232-236, 1989; and Lerman and Silverstein, Meth. Enzymol., 155:482-501, 1987). Modifications of the technique have been developed, using temperature gradients (Wartell et al., Nucl. Acids Res., 18:2699-2701, 1990), and the method can be also applied to RNA:RNA duplexes (Smith et al., Genomics 3:217-223, 1988).

Limitations on the utility of DGGE include the requirement that the denaturing conditions must be optimized for each type of DNA to be tested. Furthermore, the method requires specialized equipment to prepare the gels and maintain the needed high temperatures during electrophoresis. The expense associated with the synthesis of the clamping tail on one oligonucleotide for each sequence to be tested is also a major consideration. In addition, long running times are required for DGGE. The long running time of DGGE was shortened in a modification of DGGE called constant denaturant gel electrophoresis (CDGE) (Borrensen et al., Proc. Natl. Acad. Sci. USA 88:8405, 1991). CDGE requires that gels be performed under different denaturant conditions in order to reach high efficiency for the detection of SNPs.

A technique analogous to DGGE, termed temperature gradient gel electrophoresis (TGGE), uses a thermal gradient rather than a chemical denaturant gradient (Scholz, et al., Hum. Mol. Genet. 2:2155, 1993). TGGE requires the use of specialized equipment which can generate a temperature gradient perpendicularly oriented relative to the electrical field. TGGE can detect mutations in relatively small fragments of DNA therefore scanning of large gene segments requires the use of multiple PCR products prior to running the gel.

Single-Strand Conformation Polymorphism (SSCP): Another common method, called “Single-Strand Conformation Polymorphism” (SSCP) was developed by Hayashi, Sekya and colleagues (reviewed by Hayashi, PCR Meth. Appl., 1:34-38, 1991) and is based on the observation that single strands of nucleic acid can take on characteristic conformations in non-denaturing conditions, and these conformations influence electrophoretic mobility. The complementary strands assume sufficiently different structures that one strand may be resolved from the other. Changes in sequences within the fragment will also change the conformation, consequently altering the mobility and allowing this to be used as an assay for sequence variations (Orita, et al., Genomics 5:874-879, 1989).

The SSCP process involves denaturing a DNA segment (e.g., a PCR product) that is labeled on both strands, followed by slow electrophoretic separation on a non-denaturing polyacrylamide gel, so that intra-molecular interactions can form and not be disturbed during the run. This technique is extremely sensitive to variations in gel composition and temperature. A serious limitation of this method is the relative difficulty encountered in comparing data generated in different laboratories, under apparently similar conditions.

Dideoxy fingerprinting (ddF): The dideoxy fingerprinting (ddF) is another technique developed to scan genes for the presence of mutations (Liu and Sommer, PCR Methods Appli., 4:97, 1994). The ddF technique combines components of Sanger dideoxy sequencing with SSCP. A dideoxy sequencing reaction is performed using one dideoxy terminator and then the reaction products are electrophoresed on nondenaturing polyacrylamide gels to detect alterations in mobility of the termination segments as in SSCP analysis. While ddF is an improvement over SSCP in terms of increased sensitivity, ddF requires the use of expensive dideoxynucleotides and this technique is still limited to the analysis of fragments of the size suitable for SSCP (i.e., fragments of 200-300 bases for optimal detection of mutations).

In addition to the above limitations, all of these methods are limited as to the size of the nucleic acid fragment that can be analyzed. For the direct sequencing approach, sequences of greater than 600 base pairs require cloning, with the consequent delays and expense of either deletion sub-cloning or primer walking, in order to cover the entire fragment. SSCP and DGGE have even more severe size limitations. Because of reduced sensitivity to sequence changes, these methods are not considered suitable for larger fragments. Although SSCP is reportedly able to detect 90% of single-base substitutions within a 200 base-pair fragment, the detection drops to less than 50% for 400 base pair fragments. Similarly, the sensitivity of DGGE decreases as the length of the fragment reaches 500 base-pairs. The ddF technique, as a combination of direct sequencing and SSCP, is also limited by the relatively small size of the DNA that can be screened.

Pyrosequencing™ analysis (Pyrosequencing, Inc. Westborough, Mass., USA): This technique is based on the hybridization of a sequencing primer to a single stranded, PCR-amplified, DNA template in the presence of DNA polymerase, ATP sulfurylase, luciferase and apyrase enzymes and the adenosine 5′ phosphosulfate (APS) and luciferin substrates. In the second step the first of four deoxynucleotide triphosphates (dNTP) is added to the reaction and the DNA polymerase catalyzes the incorporation of the deoxynucleotide triphosphate into the DNA strand, if it is complementary to the base in the template strand. Each incorporation event is accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the amount of incorporated nucleotide. In the last step the ATP sulfurylase quantitatively converts PPi to ATP in the presence of adenosine 5′ phosphosulfate. This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates visible light in amounts that are proportional to the amount of ATP. The light produced in the luciferase-catalyzed reaction is detected by a charge coupled device (CCD) camera and seen as a peak in a Pyrogram™. Each light signal is proportional to the number of nucleotides incorporated.

Acycloprime™ analysis (Perkin Elmer, Boston, Mass., USA): This technique is based on fluorescent polarization (FP) detection. Following PCR amplification of the sequence containing the SNP of interest, excess primer and dNTPs are removed through incubation with shrimp alkaline phosphatase (SAP) and exonuclease I. Once the enzymes are heat inactivated, the Acycloprime-FP process uses a thermostable polymerase to add one of two fluorescent terminators to a primer that ends immediately upstream of the SNP site. The terminator(s) added are identified by their increased FP and represent the allele(s) present in the original DNA sample. The Acycloprime process uses AcycloPol™, a novel mutant thermostable polymerase from the Archeon family, and a pair of AcycloTerminators™ labeled with R110 and TAMRA, representing the possible alleles for the SNP of interest. AcycloTerminator™ non-nucleotide analogs are biologically active with a variety of DNA polymerases. Similarly to 2′,3′-dideoxynucleotide-5′-triphosphates, the acyclic analogs function as chain terminators. The analog is incorporated by the DNA polymerase in a base-specific manner onto the 3′-end of the DNA chain, and since there is no 3′-hydroxyl, is unable to function in further chain elongation. It has been found that AcycloPol has a higher affinity and specificity for derivatized AcycloTerminators than various Taq mutant have for derivatized 2′,3′-dideoxynucleotide terminators.

Reverse dot blot: This technique uses labeled sequence specific oligonucleotide probes and unlabeled nucleic acid samples. Activated primary amine-conjugated oligonucleotides are covalently attached to carboxylated nylon membranes. After hybridization and washing, the labeled probe, or a labeled fragment of the probe, can be released using oligomer restriction, i.e., the digestion of the duplex hybrid with a restriction enzyme. Circular spots or lines are visualized colorimetrically after hybridization through the use of streptavidin horseradish peroxidase incubation followed by development using tetramethylbenzidine and hydrogen peroxide, or via chemiluminescence after incubation with avidin alkaline phosphatase conjugate and a luminous substrate susceptible to enzyme activation, such as CSPD, followed by exposure to x-ray film.

It will be appreciated that advances in the field of SNP detection have provided additional accurate, easy, and inexpensive large-scale SNP genotyping techniques, such as dynamic allele-specific hybridization (DASH, Howell, W. M. et al., 1999. Dynamic allele-specific hybridization (DASH). Nat. Biotechnol. 17: 87-8), microplate array diagonal gel electrophoresis [MADGE, Day, I. N. et al., 1995. High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). Biotechniques. 19: 830-5], the TaqMan system (Holland, P. M. et al., 1991. Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA. 88: 7276-80), as well as various DNA “chip” technologies such as the GeneChip microarrays (e.g., Affymetrix SNP chips) which are disclosed in U.S. Pat. No. 6,300,063 to Lipshutz, et al. 2001, which is fully incorporated herein by reference, Genetic Bit Analysis (GBA™) which is described by Goelet, P. et al. (PCT Appl. No. 92/15712), peptide nucleic acid (PNA, Ren B, et al., 2004. Nucleic Acids Res. 32: e42) and locked nucleic acids (LNA, Latorra D, et al., 2003. Hum. Mutat. 22: 79-85) probes, Molecular Beacons (Abravaya K, et al., 2003. Clin Chem Lab Med. 41: 468-74), intercalating dye [Germer, S, and Higuchi, R. Single-tube genotyping without oligonucleotide probes. Genome Res. 9:72-78 (1999)], FRET primers (Solinas A et al., 2001. Nucleic Acids Res. 29: E96), AlphaScreen (Beaudet L, et al., Genome Res. 2001, 11(4): 600-8), SNPstream (Bell P A, et al., 2002. Biotechniques. Suppl.: 70-2, 74, 76-7), Multiplex minisequencing (Curcio M, et al., 2002. Electrophoresis. 23: 1467-72), SnaPshot (Turner D, et al., 2002. Hum Immunol. 63: 508-13), MassEXTEND (Cashman J R, et al., 2001. Drug Metab Dispos. 29: 1629-37), GOOD assay (Sauer S, and Gut I G. 2003. Rapid Commun. Mass. Spectrom. 17: 1265-72), Microarray minisequencing (Liljedahl U, et al., 2003. Pharmacogenetics. 13: 7-17), arrayed primer extension (APEX) (Tonisson N, et al., 2000. Clin. Chem. Lab. Med. 38: 165-70), Microarray primer extension (O'Meara D, et al., 2002. Nucleic Acids Res. 30: e75), Tag arrays (Fan J B, et al., 2000. Genome Res. 10: 853-60), Template-directed incorporation (TDI) (Akula N, et al., 2002. Biotechniques. 32: 1072-8), fluorescence polarization (Hsu T M, et al., 2001. Biotechniques. 31: 560, 562, 564-8), Colorimetric oligonucleotide ligation assay (OLA, Nickerson D A, et al., 1990. Proc. Natl. Acad. Sci. USA. 87: 8923-7), Sequence-coded OLA (Gasparini P, et al., 1999. J. Med. Screen. 6: 67-9), Microarray ligation, Ligase chain reaction, Padlock probes, Rolling circle amplification, Invader assay (reviewed in Shi M M. 2001. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem. 47: 164-72), coded microspheres (Rao K V et al., 2003. Nucleic Acids Res. 31: e66) and MassArray (Leushner J, Chiu N H, 2000. Mol Diagn. 5: 341-80).

It will be appreciated that nucleic acid substitutions can be also identified in mRNA molecules of the individual. Such mRNA molecules are first subjected to an RT-PCR reaction following which they are either directly sequenced or be subjected to any of the SNP detection methods described hereinabove.

As is shown in FIG. 8 and Example 2 of the Examples section which follows, sequencing of the RT-PCR product generated using the GALex6F (SEQ ID NO:23) and the GALex8R (SEQ ID NO:24) primers revealed the absence of exon 7 from the mature GALNT3 mRNA.

Thus, according to preferred embodiments of the present invention, identifying at least one nucleic acid substitution in the mRNA sequence encoding GALNT3 is effected using DNA sequencing of a GLANT3 RT-PCR product.

Downregulation or upregulation of the expression level and/or activity of GalNAc-T3 can be determined using molecular and immunological methods known in the art.

Following is a list of methods useful for detecting GALNT3 RNA level in cells of the individual.

Northern Blot analysis: This method involves the detection of a particular RNA in a mixture of RNAs. An RNA sample is denatured by treatment with an agent (e.g., formaldehyde) that prevents hydrogen bonding between base pairs, ensuring that all the RNA molecules have an unfolded, linear conformation. The individual RNA molecules are then separated according to size by gel electrophoresis and transferred to a nitrocellulose or a nylon-based membrane to which the denatured RNAs adhere. The membrane is then exposed to labeled DNA probes. Probes may be labeled using radio-isotopes or enzyme linked nucleotides. Detection may be using autoradiography, colorimetric reaction or chemiluminescence. This method allows both quantitation of an amount of particular RNA molecules and determination of its identity by a relative position on the membrane which is indicative of a migration distance in the gel during electrophoresis.

RT-PCR analysis: This method uses PCR amplification of relatively rare RNAs molecules. First, RNA molecules are purified from the cells and converted into complementary DNA (cDNA) using a reverse transcriptase enzyme (such as an MMLV-RT) and primers such as, oligo dT, random hexamers or gene specific primers. Then by applying gene specific primers and Taq DNA polymerase, a PCR amplification reaction is carried out in a PCR machine. Those of skills in the art are capable of selecting the length and sequence of the gene specific primers and the PCR conditions (i.e., annealing temperatures, number of cycles and the like) which are suitable for detecting specific RNA molecules. It will be appreciated that a semi-quantitative RT-PCR reaction can be employed by adjusting the number of PCR cycles and comparing the amplification product to known controls.

RNA in situ hybridization stain: In this method DNA or RNA probes are attached to the RNA molecules present in the cells. Generally, the cells are first fixed to microscopic slides to preserve the cellular structure and to prevent the RNA molecules from being degraded and then are subjected to hybridization buffer containing the labeled probe. The hybridization buffer includes reagents such as formamide and salts (e.g., sodium chloride and sodium citrate) which enable specific hybridization of the DNA or RNA probes with their target mRNA molecules in situ while avoiding non-specific binding of probe. Those of skills in the art are capable of adjusting the hybridization conditions (i.e., temperature, concentration of salts and formamide and the like) to specific probes and types of cells. Following hybridization, any unbound probe is washed off and the slide is subjected to either a photographic emulsion which reveals signals generated using radio-labeled probes or to a colorimetric reaction which reveals signals generated using enzyme-linked labeled probes.

In situ RT-PCR stain: This method is described in Nuovo G J, et al. [Intracellular localization of polymerase chain reaction (PCR)-amplified hepatitis C cDNA. Am J Surg Pathol. 1993, 17: 683-90] and Komminoth P, et al. [Evaluation of methods for hepatitis C virus detection in archival liver biopsies. Comparison of histology, immunohistochemistry, in situ hybridization, reverse transcriptase polymerase chain reaction (RT-PCR) and in situ RT-PCR. Pathol Res Pract. 1994, 190: 1017-25]. Briefly, the RT-PCR reaction is performed on fixed cells by incorporating labeled nucleotides to the PCR reaction. The reaction is carried on using a specific in situ RT-PCR apparatus such as the laser-capture microdissection PixCell I LCM system available from Arcturus Engineering (Mountainview, Calif.).

Following is a list of immunological detection methods which can be used to detect the level of GalNAc-T3 protein in cells of the individual.

Enzyme linked immunosorbent assay (ELISA): This method involves fixation of a sample (e.g., fixed cells or a proteinaceous solution) containing a protein substrate to a surface such as a well of a microtiter plate. A substrate specific antibody coupled to an enzyme is applied and allowed to bind to the substrate. Presence of the antibody is then detected and quantitated by a calorimetric reaction employing the enzyme coupled to the antibody. Enzymes commonly employed in this method include horseradish peroxidase and alkaline phosphatase. If well calibrated and within the linear range of response, the amount of substrate present in the sample is proportional to the amount of color produced. A substrate standard is generally employed to improve quantitative accuracy.

Western blot: This method involves separation of a substrate from other protein by means of an acrylamide gel followed by transfer of the substrate to a membrane (e.g., nylon or PVDF). Presence of the substrate is then detected by antibodies specific to the substrate, which are in turn detected by antibody binding reagents. Antibody binding reagents may be, for example, protein A, or other antibodies. Antibody binding reagents may be radiolabeled or enzyme linked as described hereinabove. Detection may be by autoradiography, calorimetric reaction or chemiluminescence. This method allows both quantitation of an amount of substrate and determination of its identity by a relative position on the membrane which is indicative of a migration distance in the acrylamide gel during electrophoresis.

Radio-immunoassay (RIA): In one version, this method involves precipitation of the desired protein (i.e., the substrate) with a specific antibody and radiolabeled antibody binding protein (e.g., protein A labeled with I¹²⁵) immobilized on a precipitable carrier such as agarose beads. The number of counts in the precipitated pellet is proportional to the amount of substrate.

In an alternate version of the RIA, a labeled substrate and an unlabelled antibody binding protein are employed. A sample containing an unknown amount of substrate is added in varying amounts. The decrease in precipitated counts from the labeled substrate is proportional to the amount of substrate in the added sample.

Fluorescence activated cell sorting (FACS): This method involves detection of a substrate in situ in cells by substrate specific antibodies. The substrate specific antibodies are linked to fluorophores. Detection is by means of a cell sorting machine which reads the wavelength of light emitted from each cell as it passes through a light beam. This method may employ two or more antibodies simultaneously.

Immunohistochemical analysis: This method involves detection of a substrate in situ in fixed cells by substrate specific antibodies. The substrate specific antibodies may be enzyme linked or linked to fluorophores. Detection is by microscopy and subjective or automatic evaluation. If enzyme linked antibodies are employed, a colorimetric reaction may be required. It will be appreciated that immunohistochemistry is often followed by counterstaining of the cell nuclei using for example Hematoxyline or Giemsa stain.

Following is a list of enzymatic activity assays which can be used to determine GalNAc-T3 activity in cells of the individual.

In situ activity assay: According to this method, a chromogenic substrate is applied on the cells containing an active enzyme and the enzyme catalyzes a reaction in which the substrate is decomposed to produce a chromogenic product visible by a light or a fluorescent microscope.

In vitro activity assays: In these methods the activity of a particular enzyme is measured in a protein mixture extracted from the cells. The activity can be measured in a spectrophotometer well using colorimetric methods or can be measured in a non-denaturing acrylamide gel (i.e., activity gel). Following electrophoresis the gel is soaked in a solution containing a substrate and calorimetric reagents. The resulting stained band corresponds to the enzymatic activity of the protein of interest. If well calibrated and within the linear range of response, the amount of enzyme present in the sample is proportional to the amount of color produced. An enzyme standard is generally employed to improve quantitative accuracy.

The activity assays described hereinabove can use any of the GalNAc-T3 specific substrates, including, but not limited to, HIV_(HIB)gp120, Fibronectin, Prion-a, CD59, Muc1a, Muc2, EA2, Muc7.

It will be appreciated that mutations which downregulate the expression level and/or activity level of GalNAc-T3 can be also identified in a polypeptide sequence of the individual.

Thus, according to another aspect of the present invention there is provided a method of diagnosing familial tumoral calcinosis in an individual.

The method is effected by identifying in a polypeptide sequence of the individual at least one amino acid substitution capable of downregulating the expression level and/or activity of GalNAc-T3.

As used herein, the phrase “one amino acid substitution” refers to any change in a polypeptide sequence (e.g., substitution, deletion, duplication, methylation, acetylation, glycosylation, phosphorylation of an amino acid) which can cause downregulation of the expression level and/or activity of the GalNAc-T3.

According to preferred embodiments of the present invention the amino acid substitution is identified in the GalNAc-T3 protein as set forth in SEQ ID NO:28.

Amino acid substitutions can be identified using any method known in the art, preferably, using an antibody which is capable of identifying between two polymorphs of the same protein.

The term “polymorph” as used herein refers to one form of a protein which is different in at least one amino acid or a modification on at least one amino acid from another form of the same protein. For example, the substitution of a methionine residue with a valine residue of a certain protein. In this case one protein polymorph contains the methionine and the other protein polymorph contains the valine. Other protein polymorphs can be identified by the presence or absence of specific post-translational modifications such as the phosphorylation of a serine, threonine or tyrosine residue in a protein.

Determination of at least one amino acid substitution between two polymorphs of the GalNAc-T3 can be accomplished directly, by analyzing the GalNAc-T3 protein, or portions thereof. Such a direct analysis is often accomplished using an immunological detection method as described hereinabove.

As is mentioned before, agents which upregulate or downregulate GalNAc-T3 expression level and/or activity can be used to treat hyperphosphatemia or hypophosphatemia, respectively. Additional examples of such agents can be identified via in vitro and/or ex vivo assays.

Thus, according to another aspect of the present invention there is provided a method of identifying an agent suitable for treating a disorder associated with abnormal phosphate metabolism.

The method is effected by exposing GalNAc-T3 or cells expressing GalNAc-T3 to a plurality of molecules and selecting from them at least one molecule capable of regulating the expression level and/or the activity of the GalNAc-T3, such a molecule being the agent suitable for treating the disorder associated with abnormal phosphate metabolism.

As used herein, “exposing GalNAc-T3” refers to subjecting a GalNAc-T3 protein preparation to various test molecules. A GalNAc-T3 protein preparation can be obtained by extracting proteins from cells or tissues exhibiting high expression level of GalNAc-T3 (e.g., skin, kidney, blood) or by purifying a protein extract of eukaryotic cells which over-express the GalNAc-T3 protein. Preferably, the GalNAc-T3 protein includes at least a catalytic (i.e., the region in the protein which is responsible for the catalytic activity of the protein) or binding (i.e., the region in the protein which is responsible for binding a substrate, receptor and the like) portion of the GalNAc-T3. For example, the catalytic domain of the GalNAc-T3, which includes the amino acids at positions 566-1122 of the GalNAc-T3 protein (GenBank Accession No. NP_(—)004473, SEQ ID NO:28) can be used along with the present invention.

According to preferred embodiments of the present invention the GalNAc-T3 protein is set forth in SEQ ID NO:28.

The phrase “cells expressing GalNAc-T3” refers to eukaryotic cells, preferably mammalian cells, more preferably, human cells, which were transfected with an expression vector containing the GALNT3 polynucleotide (e.g., GenBank Accession No. NM_(—)004482, SEQ ID NO:29) and are cultured in a tissue culture flask. Non-limiting examples of such cells include bone marrow cell, kidney cells, fibroblasts, epithelial cells and lymphoblastoid cells.

Once the GalNAc-T3 or cells expressing GalNAc-T3 are obtained, the test molecules (e.g., drugs, minerals, vitamins, and the like) are applied on the GalNAc-T3 or cells expressing GalNAc-T3 and the expression level and/or activity of GalNAc-T3 is detected using the molecular, immunological and biochemical methods which are fully described hereinabove. Molecules which exert significant modulations of GalNAc-T3 activity and/or expression level (i.e., upregulation or downregulation) become candidates for additional evaluations as suitable for treating disorders associated with abnormal phosphate metabolism.

The agents of the present invention which are described hereinabove may be included in a diagnostic kit/article of manufacture preferably along with appropriate instructions for use and labels indicating FDA approval for use in diagnosing familial tumoral calcinosis and/or identifying agents suitable for treating a disorder associated with abnormal phosphate metabolism.

Such a kit can include, for example, at least one container including at least one of the above described diagnostic agents (e.g., for identifying nucleic acid substitution) and an imaging reagent packed in another container (e.g., enzymes, buffers, chromogenic substrates, fluorogenic material). The kit may also include appropriate buffers and preservatives for improving the shelf-life of the kit.

As used herein the term “about” refers to ±10%.

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., Ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA”, Scientific American Books, New York; Birren et al. (Eds.) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis, J. E., Ed. (1994); “Culture of Animal Cells—A Manual of Basic Technique” by Freshney, Wiley-Liss, N.Y. (1994), Third Edition; “Current Protocols in Immunology” Volumes I-III Coligan J. E., Ed. (1994); Stites et al. (Eds.), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (Eds.), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., Ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., Eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., Eds. (1984); “Animal Cell Culture” Freshney, R. I., Ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications”, Academic Press, San Diego, Calif. (1990); Marshak et al., “Strategies for Protein Purification and Characterization—A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Example 1 Characterization of a Familial Tumoral Calcinosis (FTC) Critical Region

Familial tumoral calcinosis (FTC; MIM211900) is a severe autosomal recessive metabolic disorder manifesting with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. To identify the genetic basis of FTC, linkage analysis was performed using DNA from informative FTC families, as follows.

Materials and Experimental Methods

FTC affected individuals—A total of 12 FTC affected individuals belonging to two large kindred of Druze and African American origin (FIGS. 1 a-b), which have been extensively described in the literature (Steinherz, R. et al. 1985, Am. J. Dis. Child. 139: 816-819; Slavin, R. E., et al., 1993, Am. J. Surg. Path. 17: 788-802) were included in the study.

Linkage analysis—A genome wide scan using 362 microsatellite markers (InVitrogen, Cat. No. 20508, Huntsville, Ala., USA) was employed in a consanguinity FTC family (family 1, FIG. 1 a).

RT-PCR analysis—RNA was extracted using the QIAGEN RNeasy kit (QIAGEN Inc., CA USA) from the following human cells or tissues: liver, heart, kidney, pancreas, skeletal muscle, bone marrow, lung, brain, placenta, retina, and skin. RT-PCR reactions were performed using the TITAN One Tube RT-PCR kit (Roche Molecular Biochemicals, Mannheim, Germany) and the GALex6F (SEQ ID NO:23) and GALex9R primers, following by a nested PCR reaction using the GALex6F and GALex8R (SEQ ID NO:24) primers (see Table 1, hereinbelow).

TABLE 1 RT-PCR primers and conditions Anneal. Primer Temp. (SEQ ID NO:) Sequence 5′→3′ (° C.) GALex6F GGCAGTTGGAGATTATGCCTTG 60° C. (SEQ ID NO:23) GALex8R CAACATCCAGACATAGAGGCTG 60° C. (SEQ ID NO:24) GALex9R CTGCTCTCCAGTGACAACTGTC 60° C. (SEQ ID NO:25) Beta Actin 5′ CGACGAGGCCCAGAGCAAGAGA 60° C. (SEQ ID NO:26) Beta Actin 3′ TCCAGGGCGACGTAGCACAGCTT 60° C. (SEQ ID NO:27)

Experimental Results

Clinical characteristics of FTC affected individuals—All twelve FTC affected individuals reported recurrent painful, calcified subcutaneous masses of up to 1 kg (FIG. 2 a), often resulting in secondary infection and incapacitating mutilation. Three patients developed deep periarticular tumors (FIG. 2 b) and one patient succumbed to the disease. All patients displayed hyperphosphatemia [range (mg/dl): family 1: 6.2-8.5; family 2: 5.2-6.6] but normal levels of calcium, parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 (Vitamin D3).

Mapping of the FTC gene to chromosome 2q24-q31—Consanguinity in family 1 enabled the application of homozygosity mapping to identify a 15 Mb segment identical by descent in all affected individuals. This region is flanked by D2S142 and D2S2284/D2S2177 markers on 2q24-q31 (FIG. 1 a). As is shown in FIG. 3 a, a maximum multipoint LOD score of 6.7 was observed for the 15 Mb region using the MAPMAKER/HOMOZ (Kruglyak L, et al., 1995. Rapid multipoint linkage analysis of recessive traits in nuclear families, including homozygosity mapping. Am. J. Hum. Genet. 56: 519-27). Multipoint linkage analysis in family 2 using 7 markers in this critical region further reduced the interval to 3 Mb, flanked by D2S111 and D2S1776 (FIG. 1 b) and yielded a maximum multipoint LOD score of 3.4 (FIG. 3 b) using the GeneHunter (Kruglyak, L., et al., 1996, Am. J. Hum. Genet. 58: 1347-1363).

Analysis of FTC putative genes in the FTC critical region—Using the Mapviewer tool available via the NCBI web site (www.ncbi.nlm.nih.gov/), 11 genes were identified within the FTC region, among which B3GALT1, SCN7A, SCN9A, SCN1A, STK39 are thought to play a role in neural or neuroendocrine tissues, while the function of TAIP-2, CMYA3, FLJ11457, LOC90643, LOC253782 is mostly unknown. The last positional candidate gene, GALNT3, encodes the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3) (Bennett, E. P., et al., 1996, Biol. Chem. 271: 17006-17012). The GalNAc-T3 protein belongs to a large family of Golgi-associated biosynthetic enzymes that transfer GalNac from the sugar donor UDP-GalNac to serine and threonine residues, and thereby are responsible for initiating O-glycan synthesis, a prevalent form of post-translational modification (Ten Hagen, K. G., et al., 2003. Glycobiology 13: IR-16R).

Tissue specific expression of the GALNT3 gene in skin and kidney—To determine if the GALNT3 gene is a putative FTC candidate gene, the expression pattern of the gene was determined using RT-PCR analysis. As is shown in FIG. 4, high level of expression was detected in RNA from both kidney and skin, two tissues of functional relevance to the pathogenesis of FTC [Steinherz, 1985 (Supra); Slavin, 1993 (Supra)].

These results demonstrate the identification of a 3 MB FTC critical region on chromosome 2q24-q31. Furthermore, the high expression level of GALNT3 in both kidney and skin suggest its involvement in the pathogenesis of FTC.

Example 2 Biallelic Deleterious Mutations in GALNT3, Encoding a Protein Involved in O-Linked Glycosylation, Cause Familial Tumoral Calcinosis

To test whether mutations in the GALNT3 gene underlie the molecular basis of FTC, genomic DNA from FTC cases was subjected to sequence analysis of the GALNT3 coding sequence.

Materials and Experimental Methods

Sequencing analysis—Genomic DNA was amplified using PCR primers designed specific for the amplification of the GALNT3 coding exons. PCR primers and conditions are listed in Table 2, hereinbelow.

TABLE 2 PCR primers and conditions Anneal. Primer Temp. (SEQ ID NO:) Sequence 5′→3′ (° C.) GALe1bR GCTCACCCCTCTCTCCCCTG 60° C. (SEQ ID NO:1) GALe1bF CATTGATGCTGGTGAGAG (SEQ ID NO:2) GALe1aR CTGAGGTGGACGGTCAAGGACAG 60° C. (SEQ ID NO:3) GALe1Af GTAGGACTGAATAGCTACTAATAC (SEQ ID NO:4) GALe2R CTGAGATGGCATACAGAGAGTAC 60° C. (SEQ ID NO:5) GALe2F CTCTGGGTGAGTGATTTGCTTG (SEQ ID NO:6) GALe3R CACAGAGCTGTTACCTGCTTGG 60° C. (SEQ ID NO:7) GALe3F GCTCTGTGGTTTCATTAGCTTTC (SEQ ID NO:8) GALe4R GCTATAAAGCAAACAGTGTGTAC 60° C. (SEQ ID NO:9) GALe4F CAATAAATCTGAGGAAGAAAGAAATC (SEQ ID NO:10) GALe5R GTGCACACATCTGTAATCATATG 60° C. (SEQ ID NO:11) GALe5F CAATGGGAGAGGACACGAAGTAC (SEQ ID NO:12) GALe6R GAATCGACGCAAAAGGACGTG 60° C. (SEQ ID NO:13) GALe6F GAAATGGCAGGGGACAGAGAC (SEQ ID NO:14) GALe7R GTAAAATCTCAAAAGCAATAAAGAAAG 60° C. (SEQ ID NO:15) GALe7F CAGAAATGAACAGGCAGGCATG (SEQ ID NO:16) GALe8R GCAACATCTCACTTGTGCTTG 60° C. (SEQ ID NO:17) GALe8F GATACGTGAGTATTTTCCTGTTCC (SEQ ID NO:18) GALe9R GATATATTCTCTTATCACATGGG 60° C. (SEQ ID NO:19) GALe9F GGCTATTGTATCGTCTATCAC (SEQ ID NO:20) GALe10R CTACAGTGTATGCCTAGTCACAG 60° C. (SEQ ID NO:21) GALe10F CTGTCTGCCTCTCTTCATTATG (SEQ ID NO:22)

Experimental Results

FTC patients of family 2 are compound heterozygous of a nonsense mutation in exon 1 and a splice mutation in intron 7 of GALNT3—As is shown in FIGS. 5 a-b, affected individuals of family 2 were found to be carriers of a nonsense mutation in exon 1, in which a C→T substitution resulted in a change of the CGA codon of Arginine at position 162 of the GALNT3 protein (GenBank Accession No. NP_(—)004473 SEQ ID NO:28) with a termination codon (i.e., TGA). Moreover, as is shown in FIG. 5 c-d, the same affected individuals of family 2 were carriers of a splice mutation in intron 7 at position 1524+5G→A from the ATG translation start site (GLANT3 mRNA sequence—GenBank Accession No. NM_(—)004482, SEQ ID NO:29; GLANT3 genomic contig—GenBank Accession No. NT_(—)005403).

Homozygous splice mutation in intron 7 of the consanguinity Druze FTC family 1—Sequence analysis of all 10 coding exons of the GALNT3 gene from the Druze family revealed the presence of a homozygous G→A transition at position 1524+1 (from the ATG translation start site GenBank Accession No. NM_(—)004482, SEQ ID NO: 29), resulting in the disruption of the intron 7 donor splice site consensus sequence (FIGS. 5 c-d).

Noteworthy, all three mutations (i.e., 1524+1G→A; 1524+5G→A, R162X) were excluded from a panel of at least 290 chromosomes derived from healthy unrelated individuals.

Furthermore, as can be seen in FIGS. 6 a-b, a complete co-segregation of the mutations with the disease phenotype was confirmed by PCR-RFLP in both FTC families.

Analysis and Discussion—The nonsense R162X mutation is expected to result in a non-functional null allele due to premature termination of protein translation. Mutations 1524+1G→A and 1524+5G→A alter the same splice donor site in intron 7. In contrast to the normal splicing score of 0.93 obtained for the intron 7 splice donor site predicted by the Splice Site Prediction by Neural Network software (http://www.fruitfly.org/seq_tools/splice.html), the calculated score of this sequence carrying a G→A mutation at position 1524+1 or 1524+5 was 0.00.

The 1524+1G→A splice mutation results in an absence of exon 7 from the GALNT3 mRNA transcript—To further assess the consequences of the 1524+1G→A splice site mutation, the expression pattern of GALNT3 was assessed using RT-PCR. As shown in FIG. 7, while a normal band of approximately 600 bp was detected in skin and blood samples of a healthy individual, no wildtype GALNT3 transcript was detected in RNA from affected individuals. In addition, low amounts of an aberrant splice variant were detected in RNA derived from both skin and blood samples. Sequence analysis of the aberrant shorter transcript revealed the presence of a shorter GALNT3 transcript lacking exon 7 nucleotide sequence (FIG. 8). This shorter mRNA transcripts results in an in-frame deletion of 44 amino acid residues in the mature polypeptide, destroying most of the linker region located between the catalytic domain and the ricin-like domain of the glycosyltransferase.

Altogether, these results demonstrate that deleterious mutations in the GALNT3 sequence underlie the molecular basis of FTC.

Analysis and Discussion—Since the original description of FTC more than a century ago by Giard, J. M, 1898 (Sur la calcification hibernale. Compes. Rend. Seanes. Soc. Biol. So. 1013-1015), the pathogenesis of this disease has stirred up a large number of investigations but has remained mostly elusive.

The results presented here suggest a role for GalNAc-T3-mediated glycosylation in the control of phosphatonin activity. Although the NetOGlyc 3.0 software (http://www.cbs.dtu.dk/services/NetOGlyc) identified potential O-glycosylation sites in FGF23 (setting O-glycosylation score significance at >0.5), this molecule is unlikely to mediate the deleterious effects of GALNT3 mutations in FTC. Indeed, impaired FGF23 activity in a murine model was recently shown to lead to prominent bone tissue abnormalities [Shimada, T et al. J Clin Invest. 113, 561-568 (2004)], which are absent in FTC patients. Of note, FGF23 circulating levels measured by ELISA (Immutopics, CA) were significantly elevated in 6 FTC patients (1710+864 RU/ml) as compared with 6 healthy controls (56+38 RU/ml), possibly reflecting a compensatory response to hyperphosphatemia. Thus GalNAc-T3 may affect phosphate homeostasis by modulating the activity of another phosphatonin or PHEX [Jan De Beur, 2002 (Supra)]. Alternatively, it may directly regulate non-circulating elements within tissues where GALNT3 is expressed such as the skin, where calcium deposition occurs [Steinherz, 1985 (Supra); Slavin, 1993 (Supra)], the bone, where candidate phosphatonins are expressed [Schiavi, 2004 (Supra); Quarles, 2003. (Supra)], and/or the kidneys and gastrointestinal tract, where phosphate transport occurs [Jan De Beur, 2002, (Supra)]. Given the existence of more than 20 ppGaNTase isoforms [Ten Hagen, 2003 (Supra)] substrate specificity and/or functional redundancy may account for the restricted nature of the FTC phenotype despite GALNT3 widespread tissue expression.

GalNAc-T3 may not be the sole regulator of phosphate homeostasis in peripheral tissues. Prince et al [Prince M. J. et al. Ann Intern Med. 96, 586-591 (1982)] established 2 decades ago that FTC can also present with normal phosphate levels. Using haplotype analysis in four families with normophosphatemic FTC, this FTC variant was excluded from linkage to 2q24-q31 (not shown), suggesting that normophosphatemic and hyperphosphatemic FTC are non-allelic disorders.

In summary, these results establish autosomal recessive mutations in GALNT3 as the molecular cause of hyperphosphatemic FTC and demonstrate the pathological consequences of a genetic defect in a mucin-type O-glycosylation pathway. The identification of the FTC gene should not only benefit the affected families, to which molecular testing can now be offered, but may also shed new light on the mechanisms regulating phosphate metabolism in health and disease, with obvious implications for the treatment of acquired disorders manifesting with hyperphosphatemic calcinosis, such as chronic renal failure.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. 

1-34. (canceled)
 35. A method of treating a disorder associated with abnormal phosphate metabolism comprising providing to an individual in need thereof an agent capable of regulating an expression level and/or activity of GalNAc-T3, thereby treating the disorder associated with abnormal phosphate metabolism in said individual.
 36. The method of claim 35, wherein said disorder is associated with hyperphosphatemia.
 37. The method of claim 36, wherein said disorder associated with hyperphosphatemia is selected from the group consisting of familial tumoral calcinosis (FTC), hyperphosphatemic calcinosis, hemodialysis and chronic renal failure.
 38. The method of claim 35, wherein said regulating is upregulating said expression level and/or activity of said GalNAc-T3, said upregulating is effected by an agent selected from the group consisting of: (a) an exogenous polynucleotide encoding at least a functional portion of GALNT3; (b) an agent capable of increasing expression of endogenous GalNAc-T3 in an individual; (c) an agent capable of increasing endogenous GalNAc-T3 activity in an individual; (d) an exogenous polypeptide including at least a functional portion of GalNAc-T3; (e) a GalNAc-T3 substrate; and (f) a GalNAc-T3-expressing cell.
 39. The method of claim 38, wherein said exogenous polynucleotide encoding at least a functional portion of GALNT3 is set forth in SEQ ID NO:29.
 40. The method of claim 35, wherein said disorder is associated with hypophosphatemia.
 41. The method of claim 40, wherein said disorder associated with said hypophosphatemia is selected from the group consisting of X-linked vitamin D resistant hypophosphatemic rickets (HYP), hereditary hypercalciuria with hypophosphatemic rickets (HHRH), oncogenic hypophosphatemic osteomalacia (OHO) and X-linked hypophosphatemic rickets (PHEX).
 42. The method of claim 35, wherein said regulating is downregulating said expression level and/or said activity of said GalNAc-T3, said downregulating is effected by an agent selected from the group consisting of: (a) a molecule which binds said GalNAc-T3; (b) an enzyme which cleaves said GalNAc-T3; (c) an antisense polynucleotide capable of specifically hybridizing with at least part of an mRNA transcript encoding GALNT3; (d) a ribozyme which specifically cleaves at least part of an mRNA transcript encoding GALNT3; (e) a small interfering RNA (siRNA) molecule which specifically cleaves at least part of a transcript encoding GALNT3; (f) a non-functional analogue of at least a catalytic or binding portion of said GalNAc-T3; (g) a molecule which prevents GalNAc-T3 activation or substrate binding.
 43. The method of claim 42, wherein said mRNA transcript encoding GALNT3 is set forth in SEQ ID NO:29.
 44. A method of diagnosing familial tumoral calcinosis (FTC) in an individual, the method comprising identifying in a polynucleotide sequence of the individual at least one nucleic acid substitution resulting in downregulation of an expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.
 45. The method of claim 44, wherein said polynucleotide sequence is an mRNA sequence encoding GALNT3 or a genomic sequence region including the GALNT3 gene.
 46. A method of diagnosing familial tumoral calcinosis in an individual, the method comprising identifying in a polypeptide sequence of the individual at least one amino acid substitution capable of downregulating expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.
 47. The method of claim 46, wherein said polypeptide sequence is set forth in SEQ ID NO:28.
 48. The method of claim 46, wherein said identifying said at least one amino acid substitution is effected using an antibody capable of differentially binding to at least one polymorph of said GalNAc-T3, said at least one polymorph includes said amino acid substitution capable of downregulating said expression level and/or said activity of GalNAc-T3.
 49. A kit for diagnosing familial tumoral calcinosis in an individual, the kit comprising a packaging material packaging at least one reagent and instructions for use in diagnosing familial tumoral calcinosis, said at least one reagent for identifying in a polynucleotide sequence of the individual at least one nucleic acid substitution resulting in downregulation of an expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.
 50. The kit of claim 49, wherein said polynucleotide sequence is an mRNA sequence encoding GALNT3 or a genomic sequence region including the GALNT3 gene.
 51. A kit for diagnosing familial tumoral calcinosis in an individual, the kit comprising a packaging material packaging at least one reagent and instructions for use in diagnosing familial tumoral calcinosis, said at least one reagent for identifying in a polypeptide sequence of the individual at least one amino acid substitution capable of downregulating expression level and/or activity of GalNAc-T3, thereby diagnosing familial tumoral calcinosis in the individual.
 52. The kit of claim 51, wherein said polypeptide sequence is set forth in SEQ ID NO:28.
 53. The kit of claim 51, wherein said reagent for identifying said at least one amino acid substitution comprises an antibody capable of differentially binding to at least one polymorph of said GalNAc-T3, said at least one polymorph includes said amino acid substitution capable of downregulating said expression level and/or said activity of GalNAc-T3. 